Journal of Vascular Surgery
Volume 45, Issue 1 , Pages 47-54 , January 2007

The course of vascular risk factors and the occurrence of vascular events in patients with symptomatic peripheral arterial disease

  • Bertine M.B. Goessens, MSc

      Affiliations

    • Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands
    • ,
  • Yolanda van der Graaf, MD, PhD

      Affiliations

    • Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands
    • Corresponding Author InformationReprint requests: Yolanda van der Graaf, MD, PhD, Julius Center for Health Sciences and Primary Care, UMC Utrecht, Str 6.131, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.
    • ,
  • Jobien K. Olijhoek, MD

      Affiliations

    • Internal Medicine, Section of Vascular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.
    • ,
  • Frank L.J. Visseren, MD, PhD

      Affiliations

    • Internal Medicine, Section of Vascular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.
    • ,
  • SMART Study Group

Received 14 July 2006 ,Accepted 6 September 2006.

References 

  1. Baumgartner I, Schainfeld R, Graziani L. Management of peripheral vascular disease. Annu Rev Med. 2005;56:249–272
  2. Ouriel K. Peripheral arterial disease. Lancet. 2001;358:1257–1264
  3. Bittl JA, Hirsch AT. Concomitant peripheral arterial disease and coronary artery disease: therapeutic opportunities. Circulation. 2004;109:3136–3144
  4. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326:381–386
  5. Vickrey BG, Rector TS, Wickstrom SL, Guzy PM, Sloss EM, Gorelick PB, et al. Occurrence of secondary ischemic events among persons with atherosclerotic vascular disease. Stroke. 2002;33:901–906
  6. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145–153
  7. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389
  8. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86
  9. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:23–33
  10. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853
  11. Neal B, MacMahon S, Chapman N Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet. 2000;356:1955–1964
  12. Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286:1317–1324
  13. McDermott MM, Hahn EA, Greenland P, Cella D, Ockene JK, Brogan D, et al. Atherosclerotic risk factor reduction in peripheral arterial disease: results of a national physician survey. J Gen Intern Med. 2002;17:895–904
  14. Rehring TF, Sandhoff BG, Stolcpart RS, Merenich JA, Hollis HW. Atherosclerotic risk factor control in patients with peripheral arterial disease. J Vasc Surg. 2005;41:816–822
  15. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2003;24:1601–1610
  16. Simons PC, Algra A, van de Laak MF, Grobbee DE, van der Graaf Y. Second Manifestations of ARTerial disease (SMART) study: rationale and design. Eur J Epidemiol. 1999;15:773–781
  17. Rose GA, Blackburn H. Cardiovascular survey methods. Monogr Ser World Health Organ. 1968;56:1–188
  18. Pentecost MJ, Criqui MH, Dorros G, Goldstone J, Johnston KW, Martin EC, et al. Guidelines for peripheral percutaneous transluminal angioplasty of the abdominal aorta and lower extremity vessels (A statement for health professionals from a special writing group of the Councils on Cardiovascular Radiology, Arteriosclerosis, Cardio-Thoracic and Vascular Surgery, Clinical Cardiology, and Epidemiology and Prevention, the American Heart Association). Circulation. 1994;89:511–531
  19. Burns P, Lima E, Bradbury AW. Second best medical therapy. Eur J Vasc Endovasc Surg. 2002;24:400–404
  20. Henke PK, Blackburn S, Proctor MC, Stevens J, Mukherjee D, Rajagopalin S, et al. Patients undergoing infrainguinal bypass to treat atherosclerotic vascular disease are underprescribed cardioprotective medications: effect on graft patency, limb salvage, and mortality. J Vasc Surg. 2004;39:357–365
  21. Mukherjee D, Lingam P, Chetcuti S, Grossman PM, Moscucci M, Luciano AE, et al. Missed opportunities to treat atherosclerosis in patients undergoing peripheral vascular interventions: insights from the University of Michigan Peripheral Vascular Disease Quality Improvement Initiative (PVD-QI2). Circulation. 2002;106:1909–1912
  22. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295:180–189
  23. Kalman PG, Irvine J, Ritvo P. How do vascular surgeons perceive atherosclerotic risk factor management?. Ann Vasc Surg. 2000;14:652–658
  24. Caro J, Migliaccio-Walle K, Ishak KJ, Proskorovsky I. The morbidity and mortality following a diagnosis of peripheral arterial disease: long term follow-up of a large database. BMC Cardiovasc Disord. 2005;5:14
  25. Muluk SC, Muluk VS, Kelley ME, Whittle JC, Tierney JA, Webster MW, et al. Outcome events in patients with claudication: a 15-year study in 2777 patients. J Vasc Surg. 2001;33:251–257
  26. Nicoloff AD, Taylor LM, Sexton GJ, Schuff RA, Edwards JM, Yeager RA, et al. Relationship between site of initial symptoms and subsequent progression of disease in a prospective study of atherosclerosis progression in patients receiving long-term treatment for symptomatic peripheral arterial disease. J Vasc Surg. 2002;35:38–46
  27. Cattaneo M. Is hyperhomocysteinemia an important risk factor of cardiovascular disease?. Pathophysiol Haemost Thromb. 2003;33:345–347
  28. Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354:1578–1588
  29. Aboyans V, Criqui MH, Denenberg JO, Knoke JD, Ridker PM, Fronek A. Risk factors for progression of peripheral arterial disease in large and small vessels. Circulation. 2006;113:2623–2629
  30. Kaplan RC, Heckbert SR, Furberg CD, Psaty BM. Predictors of subsequent coronary events, stroke, and death among survivors of first hospitalized myocardial infarction. J Clin Epidemiol. 2002;55:654–664
  31. Goessens BM, Visseren FL, Olijhoek JK, Eikelboom BC, van der Graaf Y. Multidisciplinary vascular screening program modestly improves the medical treatment of vascular risk factors. Cardiovasc Drugs Ther. 2005;19:429–435
  32. Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004;351:2058–2068
  33. Schillinger M, Exner M, Mlekusch W, Amighi J, Sabeti S, Muellner M, et al. Statin therapy improves cardiovascular outcome of patients with peripheral artery disease. Eur Heart J. 2004;25:742–748
  34. Pedersen TR, Kjekshus J, Pyorala K, Olsson AG, Cook TJ, Musliner TA, et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). Am J Cardiol. 1998;81:333–335
  35. Mondillo S, Ballo P, Barbati R, Guerrini F, Ammaturo T, Agricola E, et al. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am J Med. 2003;114:359–364
  36. Goessens BM, Visseren FL, Sol BG, de Man-van Ginkel JM, van der Graaf Y. A randomised controlled trial for risk factor reduction in patients with symptomatic vascular disease: the multidisciplinary Vascular prEvention by NUrses Study (VENUS). Eur J Cardiovasc Prev Rehabil. 2006;13:996–1003

 Competition of interest: none.

PII: S0741-5214(06)01668-5

doi: 10.1016/j.jvs.2006.09.015

Journal of Vascular Surgery
Volume 45, Issue 1 , Pages 47-54 , January 2007

Article Tools